Global /Canada /Healthcare /Biotechnology /ABCL

AbCellera Biologics Inc.

ABCL

• NASDAQ: ABCL • Delayed

3.82USD -8.2%

As of 5 June 2026, AbCellera Biologics Inc. has a market cap of $1.16B USD, ranking #9898 globally and #262 in Canada. It ranks #869 in the Healthcare sector, and #160 in the Biotechnology industry.

Global Rank

9898

Country Rank

262

Sector Rank

869

Industry Rank

160

Key Stats

Market Cap

$1.16BUSD

Enterprise Value

$767.47MUSD

Revenue (TTM)

$75.13MUSD

EBITDA (TTM)

-$194.93MUSD

Net Income (TTM)

-$146.41MUSD

EBITDA Margin

-259%

Profit Margin

-195%

PS Ratio

15.4

PB Ratio

1.2

Company Profile

Country (HQ)

Canada

Sector

Healthcare

Industry

Biotechnology

CEO

Carl Hansen open_in_new

Employees

562

Founded

2012

IPO

11 Dec 2020

Website

abcellera.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-8.2%	-6.4%	17%	-2.1%	-32%	12%	47%	-44%	-87%

News

ABCL Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	ABCL AbCellera Biologics Inc Ordinary Shares ISIN: CA00288U1066 Shares Out.: Shares Outstanding: 305.375M¹ Shares Float: 234.505M² TV: TradingView: NASDAQ: ABCL SA: Stock Analysis: NASDAQ: ABCL YF: Yahoo Finance: ABCL GF: Google Finance: NASDAQ: ABCL NQ: NASDAQ: ABCL BA: Barron's: ABCL MS: Morningstar: XNAS: ABCL	3.82 USD	TV: TradingView: NASDAQ: ABCL SA: Stock Analysis: NASDAQ: ABCL YF: Yahoo Finance: ABCL GF: Google Finance: NASDAQ: ABCL NQ: NASDAQ: ABCL BA: Barron's: ABCL MS: Morningstar: XNAS: ABCL
Frankfurt Stock Exchange (FRA) MIC: XFRA	8QQ AbCellera Biologics Inc Ordinary Shares ISIN: CA00288U1066 TV: TradingView: FWB: 8QQ SA: Stock Analysis: FRA: 8QQ YF: Yahoo Finance: 8QQ.F GF: Google Finance: FRA: 8QQ BA: Barron's: 8QQ MS: Morningstar: XFRA: 8QQ	3.43 EUR	TV: TradingView: FWB: 8QQ SA: Stock Analysis: FRA: 8QQ YF: Yahoo Finance: 8QQ.F GF: Google Finance: FRA: 8QQ BA: Barron's: 8QQ MS: Morningstar: XFRA: 8QQ

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About AbCellera Biologics Inc.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Similar Companies

Industry: Biotechnology (Canada)

Name	Market Cap (USD) diff.	PE	Country
Aurinia Pharmaceuticals Inc. NASDAQ: AUPH	$1.99B 71%	7.4	Canada
Eupraxia Pharmaceuticals Inc. TSX: EPRX	$432.32M 600.89M CAD -63%	-	Canada
NervGen Pharma Corp. TSXV: NGEN	$295.12M 410.19M CAD -75%	-	Canada
Cybin Inc. NEO: CYBN	$254.07M 353.13M CAD -78%	-	Canada
Cardiol Therapeutics Inc. TSX: CRDL	$149.71M 208.08M CAD -87%	-	Canada
Theratechnologies Inc. TSX: TH	$147.87M 205.53M CAD -87%	-	Canada

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 16K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 14K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 4K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 4K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 4K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 4K%	37.2	Switzerland

chevron_leftBack